CNBC's Meg Tirrell discusses biotech in the bear market and what to expect going forward.
CNBC's Melissa Lee and the Options Action traders discuss the stocks they'll be watching next week.
CNBC's Meg Tirrell looks into the biotech sector and Melissa Lee and the Options Action traders give their takes on whether to hide out in the healthcare sector.
The U.K.’s Brexit vote sent global markets into a tailspin. But beyond the gloomy scenarios lie a a few short-term upsides, The Fiscal Times reports.
These stocks to buy on a pullback are the least exposed to a potential European economic crisis, according to Morgan Stanley.
Amgen Chairman and CEO Robert Bradway, provides insight to product innovation, the impact from the political cycle and the outlook for M&A.
Discussing the current state of valuation in the markets with Chad Morganlander, Stifel Portfolio Manager, and Jack Ablin, BMO Private Bank Executive VP & Chief Investment Officer.
Amgen said Wednesday that it has seen positive results for the chronic-migraine prevention drug it has been developing with Novartis.
Michael Farr, Farr Miller & Washington, and Kevin Norris, Univest Wealth Management President, discuss their summer market outlooks and give their picks.
Biotech has been at a low year-to-date, but traders believe the sector is going to make a comeback.
The biotech sector has been sliding, but a turnaround could be afoot. Chad Morganlander of Stifel Nicolaus and Craig Johnson of Piper Jaffray discuss with Brian Sullivan.
Amgen is working on a drug to lower the risk of heart attack, reports CNBC's Meg Tirrell.
Nutanix is the biggest tech name on file for an IPO. While investors wait, its co-founder is bulking up a new company — ThoughtSpot.
A rare and previously unknown variation in some people's genes substantially reduces their heart attack risk, the Icelandic researchers said.
Pfizer will buy Anacor Pharmaceuticals in a deal valued at $5.2 billion, for access to Anacor's non-steroidal topical gel to treat eczema.
U.S. stocks closed mixed in below average trade volume Monday, with gains in health care offsetting declines in materials and energy as oil fell.
Biotech stocks dragged on the market Friday, and some "Fast Money" traders contended the pain may not be done.
Three pillars of valuation driving biotech with CNBC's Meg Tirrell while the Fast Money panel discuss biotech as their top trade of the day.
The "Fast Money" traders get into biotech and give you 5 trades in a mixed sector.
Some of the names on the move ahead of the open.